ExoCoBio Inc. has been developing innovative therapeutics as well as cosmetic products based on stem
Location: South Korea, Seoul
Employees: 51-200
Total raised: $37.7M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 20.11.2023 | Quantum Ve... | quantumepk... |
| - | SBI Invest... | sbik.co.kr |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.09.2018 | Series B | $26.7M | - |
| 02.05.2017 | Series A | $11M | - |
Mentions in press and media 11
| Date | Title | Description |
| 19.05.2023 | ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™) | - The first plant stem cell-derived exosome patent in the US - The 5th patent allowance following 3 in Korea and 1 in Japan - An important milestone for the global plant stem cell-derived exosome industry SEOUL, South Korea, May 19, 2023 /P... |
| 02.03.2023 | ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA | ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. Cellosome™ HA fillers are expected to be approved in 2023. ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics.... |
| 16.08.2022 | ExoCoBio's First Global Regenerative Aesthetic Exosome Summit | World First Regenerative Aesthetic Exosome Summit (RAES 2022) Participation of Global Exosome and Regenerative Aesthetic Authorities Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, So... |
| 25.08.2021 | ExoCoBio to Build the World's First Clinical Grade Exosome GMP Manufacturing Facility | $20 million investment for a new Mfg & R&D facility Strategic platform for partnering & CDMO business SEOUL, South Korea, Aug. 25, 2021 /PRNewswire/ -- ExoCoBio Inc., the 4th largest exosome player in the world, announced the in... |
| 26.08.2020 | ExoCoBio Raises $9.3M in Pre-IPO Financing | BENEV Exosome Regenerative Complex, in collaboration with ExoCoBio and BENEV ExoCoBio, a Seoul, South Korea-based exosome-based regenerative aesthetics company, raised $9.3m in series C and Pre-IPO funding. Backers included K2 Investment Pa... |
| 25.08.2020 | ExoCoBio Inc. : raises $9.3M in Pre-IPO Financing | Its exosome-based regenerative aesthetics business is fast growing. The IPO process will be initiated and stock trading is expected in 1Q 2021 on KOSDAQ. SEOUL, South Korea, Aug. 25, 2020 /PRNewswire/ -- ExoCoBio Inc. announced that it rece... |
| 13.09.2018 | Term Sheet — Thursday, September 13 | A SUMMER OF PROMOTIONS Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop In January, BoxGroup promoted Nimi Katragadda to partner. In May, Bain Capital Ventures hired Sarah Smith as a ge... |
| 12.09.2018 | ExoCoBio Raises $26.7M in Series B Funding | ExoCoBio Inc., a Seoul, South Korea-based exosome startup, raised approx. $27m in series B funding. Backers included Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital... |
| 04.05.2017 | Term Sheet — Thursday, May 4 | ET CETERA New money: Heap, an analytics software company, has raised $27 million in Series B funding led by NEA and Menlo Ventures with participation from Initialized Capital and Pear VC. Heap CEO and co-founder Matin Movassate created the ... |
| 04.05.2017 | S Korean venture ExoCoBio raises $11m Series A | Premium South Korean venture ExoCoBio Inc has raised an $11 million Series A funding round within four months of its establishment. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Co... |
Show more